Charles D Blanke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5503388/publications.pdf

Version: 2024-02-01

38

all docs

38 3,552 17
papers citations h-index

38

docs citations

h-index g-index

38 4219
times ranked citing authors

361022

35

#	Article	IF	Citations
1	Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 2008, 26, 626-632.	1.6	951
2	Long-Term Results From a Randomized Phase II Trial of Standard-Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i> Journal of Clinical Oncology, 2008, 26, 620-625.	1.6	922
3	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	7.4	670
4	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	1.6	252
5	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. Journal of Clinical Oncology, 2016, 34, 1803-1812.	1.6	83
6	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 50
7	State-of-the Art Therapy for Gastrointestinal Stromal Tumors. Cancer Investigation, 2005, 23, 274-280.	1.3	66
8	Gastrointestinal stromal tumors. Current Treatment Options in Oncology, 2001, 2, 485-491.	3.0	64
9	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)., 2021, 9, e002990.		58
10	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology, 2019, 37, 2620-2631.	1.6	51
11	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 400-407.	6.3	44
12	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. JAMA Ophthalmology, 2015, 133, 17.	2.5	38
13	Gastrointestinal stromal tumors: Imatinib and beyond. Current Treatment Options in Oncology, 2006, 7, 427-437.	3.0	28
14	The Predictive and Prognostic Value of Sex inÂEarly-Stage Colon Cancer: A Pooled Analysis ofÂ33,345 Patients from the ACCENT Database. Clinical Colorectal Cancer, 2013, 12, 179-187.	2.3	27
15	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	6.3	25
16	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	6.3	24
17	Role of COX-2 Inhibitors in Cancer Therapy. Cancer Investigation, 2004, 22, 271-282.	1.3	22
18	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22

#	Article	IF	Citations
19	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. Cancer Medicine, 2020, 9, 2146-2152.	2.8	18
20	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer, 2013, 12, 95-102.	2.3	17
21	A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins and Other Lipid Mediators, 2005, 75, 169-172.	1.9	14
22	In response: Diabetes is a risk factor for the progression and prognosis of <scp>COVID</scp> â€19. Diabetes/Metabolism Research and Reviews, 2020, 36, e3331.	4.0	12
23	S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist, 2015, 20, 1353-1354.	3.7	10
24	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Investigational New Drugs, 2001, 19, 21-27.	2.6	9
25	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
26	Celecoxib with chemotherapy in colorectal cancer. Oncology, 2002, 16, 17-21.	0.5	8
27	Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist. Journal of Oncology Practice, 2017, 13, 693-699.	2.5	7
28	The Globalization of Cooperative Groups. Seminars in Oncology, 2015, 42, 693-712.	2.2	6
29	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
30	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer, 2021, 127, 3801-3808.	4.1	6
31	Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 721.	7.1	5
32	Current Activities of the Coalition of Cancer Cooperative Groups. Journal of the National Cancer Institute, 2019, 111, 11-18.	6.3	4
33	Chemotherapy with Cyclooxygenase-2 Inhibitors in the Treatment of Malignant Disease: Pre-Clinical Rationale and Preliminary Results of Clinical Trials., 2003, 37, 243-260.		2
34	GIST: Not Just for Surgeons Anymore!. World Journal of Surgery, 2005, 29, 362-362.	1.6	2
35	Gastrointestinal stromal tumours: three perspectives on current diagnosis and therapy. European Journal of Cancer, Supplement, 2006, 4, 1-3.	2.2	1
36	The Gift of Dying With Control. Practical Radiation Oncology, 2019, 9, 387-388.	2.1	1

#	Article	lF	CITATIONS
37	Letters to the Editor. Journal of Law, Medicine and Ethics, 2020, 48, 800-801.	0.9	1
38	Low dose versus high dose imatinib for gastrointestinal stromal tumors. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 76-77.	1.7	0